title: Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients.
abstract: OBJECTIVE
  To assess the effectiveness of a multifaceted infection control strategy in limiting the nosocomial transmission of respiratory syncytial virus (RSV) infection to patients in a bone marrow transplant (BMT) unit.
  
  
  METHODS
  Before/after trial.
  
  
  METHODS
  University-affiliated tertiary cancer center.
  
  
  METHODS
  Adult BMT recipients hospitalized during two consecutive wintertime community outbreaks of RSV infection.
  
  
  METHODS
  An infection control strategy against nosocomial RSV infection was implemented in the BMT unit in February 1993. The strategy involved prompt identification, isolation, and cohorting of RSV-infected patients; prompt therapy with aerosolized ribavirin; use of masks and gloves by anyone entering an infected BMT patient's room; screening visitors for respiratory symptoms; restricting visitation by all children under 12 years of age and all family members and other visitors with RSV symptoms; and restricting symptomatic hospital staff from working in the BMT unit.
  
  
  RESULTS
  After implementation of the multifaceted infection-control strategy, there were four cases of nosocomial RSV infection in 3,870 patient days (incidence density, 1.0 case/1,000 patient days) compared with 14 cases of nosocomial RSV infection in 3,152 patient days (incidence density, 4.4 cases/1,000 patient days) during the 1992-1993 RSV season (rate ratio, 4.4; 95% confidence interval [CI95]. 1.4-17.9: P < .01). This decrease in incidence occurred despite a comparable prevalence of community-acquired RSV cases between the two seasons (2.2% vs 3.2% in 1992-1993 and 1993-1994, respectively; prevalence ratio, 0.7; CI95, 0.2-2.1; P = 0.5).
  
  
  CONCLUSIONS
  Institution of a multifaceted infection control strategy significantly reduced the frequency of nosocomial RSV infection in a high-risk group of adult BMT recipients.
authors.affiliation: Section of Infectious Diseases, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: R
authors.initials: R
authors.lastname: Garcia
authors.forename: I
authors.initials: I
authors.lastname: Raad
authors.forename: D
authors.initials: D
authors.lastname: Abi-Said
authors.forename: G
authors.initials: G
authors.lastname: Bodey
authors.forename: R
authors.initials: R
authors.lastname: Champlin
authors.forename: J
authors.initials: J
authors.lastname: Tarrand
authors.forename: L A
authors.initials: LA
authors.lastname: Hill
authors.forename: J
authors.initials: J
authors.lastname: Umphrey
authors.forename: J
authors.initials: J
authors.lastname: Neumann
authors.forename: J
authors.initials: J
authors.lastname: Englund
authors.forename: E
authors.initials: E
authors.lastname: Whimbey
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D006235:Hand Disinfection; D006801:Humans; D015994:Incidence; D017053:Infection Control / Q000379:methods*; D007318:Inservice Training; D010356:Patient Isolation; D011482:Protective Devices; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology / Q000517:prevention & control*; D012254:Ribavirin / Q000627:therapeutic use; D012306:Risk; D013781:Texas / Q000453:epidemiology; D014789:Visitors to Patients
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin